A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

About this Study

The purpose of this study screening step is to test specific genes and proteins in your tumor sample

Sponsor Protocol ID:LUNGMAP
IRB Number:2019-0027
Actively Enrolling
Interventional
Early Phase 1
May 29, 2019
Eligibility Criteria
Both Male and Female
Yes
No
No

Inclusion CriteriaThis study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Accrual is expected to be between 750 and 1250 patients per year.

Exclusion CriteriaNone

Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute
University Hospital
Contact Information
Contact Name: Bridgett Sessions
Phone Number: 601-984-1962
Email: brellis@umc.edu
Principal Investigator:Ruckdeschel, John C, M.D.
How to participate in our Clinical Trials